Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

. Author manuscript; available in PMC: 2015 Apr 2.

Published in final edited form as: Lancet Oncol. 2014 Feb 7;15(3):323–332. doi: 10.1016/S1470-2045(14)70012-9

Figure 4. Overall survival (randomised population; censored at crossover) for patients with BRAF mutations randomly assigned to vemurafenib or to dacarbazine (cutoff Feb 1, 2012).